1 / 18

Novartis: An Analysis of the Ciba-Geigy and Sandoz Merger

Novartis: An Analysis of the Ciba-Geigy and Sandoz Merger. Team 10: Minjal Dharia - Stefanie Duda - Jennie Ma Andrew Schwartz - Siddharth Sekhri. AGENDA. History Ciba Sandoz Background Motivations and benefits of the merger Merger process Obstacles The new company: Novartis AG

koren
Download Presentation

Novartis: An Analysis of the Ciba-Geigy and Sandoz Merger

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Novartis: An Analysis of the Ciba-Geigy and Sandoz Merger Team 10: Minjal Dharia - Stefanie Duda - Jennie Ma Andrew Schwartz - Siddharth Sekhri

  2. AGENDA • History • Ciba Sandoz Background • Motivations and benefits of the merger • Merger process • Obstacles • The new company: Novartis AG • Challenges • Strategies • Opportunities • Financial performance to date

  3. THE HISTORY OF NOVARTIS Geigy f. 1758 Ciba f. 1859 Sandoz f. 1886 Ciba-Geigy f. 1970 Novartis f. 1996

  4. Ciba-Geigy Founded 1758 - Basel, Switzerland American Subsidiary Ciba-Geigy Corp – Tarrytown, NY Total Revenues = $17.5 billion Sandoz Limited Founded 1866 - Basel, Switzerland American Subsidiary Sandoz Corporation – NYC, NY Total Revenues = $13.0 billion A MERGER OF TWO EQUALS

  5. STRATEGIC SIGNIFICANCE OF MERGER • Background of rapid structural change in pharmaceutical/ biotech market • Price pressures meant decreasing growth and margins of industry • Cost-containment efforts due to high development costs • Consolidation of suppliers gave them higher pricing power • Reach an optimum mix of business segments for synergy

  6. MOTIVATION AND BENEFITS • Motivations • Shared commonalities in crop protection, seeds, agribusiness and animal health products • Jump to new business opportunities • Distance themselves from the unsure chemical markets • Benefits • Higher critical mass for key investments such as research & development • More efficient & broader marketing & distribution of products • Lower cost of financing, increased liquidity • Leaner organizational structure

  7. THE MERGER PROCESS • March-April 1996: Ciba and Sandoz announce merger plans and validate with shareholders. • July 1996: The European Union approved the merger • August 1996: U.S. Federal Trade Commission agreed to the formation of the new company in the fall of the same year. • The merger is worth $27 billion- one of the largest in international business

  8. THE MERGER PROCESS • Stock swap in which Ciba shareholders are paid a premium • Receive 1 1/15 for 1 share • Sandoz shareholders get 1 for 1 share • Sandoz shareholders obtained 55%, Ciba Geigy 45%. • Benefits of the deal: • Tax-free because both companies are Swiss • Cash outlay not required • Transaction structured as a share issue

  9. OBSTACLES • The EU and the US FTC had concerns regarding the monopolistic nature of the mergers. • Required the demerger of the Specialty Chemicals Division of Ciba and the Construction Chemicals and animal health businesses of Sandoz • Ciba and Sandoz each had three classes of stock with varying voting rights at the start of the 1990s. • Novartis had to transform the tangled equity structure into a single class of shares last year.

  10. REGULATORY CONFLICTS/TRANSLATION EXPOSURE • Reconciling according to International Accounting Standards (IAS): • IAS rules allowed companies to write off goodwill rather than depreciating it • Allowed applying pooling-of-interest accounting rules to the $27 billion Ciba-Sandoz merger, which avoided charges for goodwill- the difference between the purchase price and book value of an asset.

  11. REGULATORY CONFLICTS/TRANSLATION EXPOSURE • But, the U.S. accounting principles (GAAP) challenged both IAS rules: • The merger should include a restructuring charge for annual depreciation of 700 million Swiss Francs • Novartis had to follow US rules to list its shares in the US • Novartis would prepare its official accounts under IAS rules and offer U.S. investors a bridging statement with adjustments according to U.S. accounting principles in a footnotes • Cash flow and cash earnings per share would remain the same under both IAS and US GAAP.

  12. NOVARTIS AG • Novartis = “re-birth” toward life sciences • Market Value > $60 billion • Standing • segments of Healthcare (59%), Agrobusiness (27%), and Nutrition (27%) • Largest worldwide marketer of crop protection chemicals • Second largest seed & animal health company • Second largest pharmaceuticals company in the world • Sales = $13 billion • 4.5% share of global market sales

  13. CHALLENGES • Novartis promised annual savings of 1.8 billion Swiss Francs • Needed to get rid of 10,000 jobs or 10% of the payroll • Needed to cut drug development time from 11 to 7 years • Needed three strong selling drugs annually • To match No. 1 Glaxo PLC • Soaring costs of biotech and genetic research tools • Shares are underrepresented in the US • Listed as ADRs on the NYSE

  14. CULTURAL CLASH • Sandoz • Was autocratic and hierarchical • Operated most functions at the business segment level • Measured performance by EBIT and return on sales • Ciba • Was collegial and informal • Matrix organization • Used direct costing • Measured performance by division contribution • Novartis • Used Sandoz’s organizational system • Measured performance by EBIT and return on net assets

  15. STRATEGIES • Sold off non-core business units • Boosted R&D spending • Sharpened marketing in the US • Increased sales force and advertising • US sales jumped to 43% of revenues • Made strategic acquisitions such as Pfizer’s drug Enablex, beating out GlaxoSmithKline CEO Daniel L. Vasella

  16. WILL NOVARTIS BUY ROCHE? • Bought a 20% share in May 2001 • Now owns 32.7% • Would mean $45 billion in sales and 7% market share • Roche is opposed to any such merger • Remains to be seen how aggressive Novartis CEO Daniel L. Vasella will be.

  17. NOVARTIS ADR FINANCIAL PERFORMANCE Not yet stocks!! DEPOSITARY RECEIPTS: NOT FDIC, STATE OR FEDERAL AGENCY INSURED MAY LOSE VALUENO BANK, STATE OR FEDERAL AGENCY GUARANTEE Source: Bank of New York

  18. QUESTIONS

More Related